Note Offers, Clinical Trial Enrolments, Conference Schedules, and Technical Updates - Analyst Notes on Illumina, Merck, HCA Holdings, Thermo Fisher Scientific and PTC Therapeutics

NEW YORK, June 10, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Illumina Inc. (NASDAQ: ILMN), Merck & Co. Inc. (NYSE: MRK), HCA Holdings, Inc. (NYSE: HCA), Thermo Fisher Scientific, Inc. (NYSE: TMO) and PTC Therapeutics, Inc. (NASDAQ: PTCT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3537-100free.
--
Illumina Inc. Analyst Notes
On June 4, 2014, Illumina Inc. (Illumina) announced the Company's intention to offer c.$900 million aggregate principal amount of convertible senior notes, subject to market and other conditions. The Company stated that it proposes to offer $450 million aggregate principal amount of convertible senior notes due 2019 and $450 million aggregate principal amount of convertible senior notes due 2021. Illumina informed that it intends to grant initial purchasers a 30-day option to purchase up to an additional $67.5 million each in both aggregate principal amount of convertible senior notes due 2019 and 2021, for a total potential offering size of $1,035 million. The Company added that it will use a part of the net proceeds to finance the repurchase or repayment of a portion of its 0.25% Convertible Senior Notes due 2016 with the remainder intended for general corporate purposes. The full analyst notes on Illumina are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/ILMN/report.pdf

--
Merck & Co. Inc. Analyst Notes
On June 5, 2014, Merck & Co. Inc. (Merck) announced that the first patient has been enrolled in the Company's global Phase 3 clinical trial, ONCEMRK. According to the Company, ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Commenting on the enrollment, Peter Sklar, M.D., M.P.H., director, Clinical Research, Merck Research Laboratories, stated, "We remain dedicated to investigating new applications for ISENTRESS and to further expanding our knowledge of this HIV-1 treatment. Merck is proud to mark this notable milestone in the development of once-daily raltegravir and we look forward to continued patient enrollment worldwide over the coming months." The full analyst notes on Merck are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/MRK/report.pdf

--
HCA Holdings, Inc. Analyst Notes
On June 3, 2014, HCA Holdings, Inc. (HCA Holdings) announced that it will present at two upcoming healthcare conferences in June 2014: Goldman Sachs Healthcare Conference on June 10, 2014 at 2:00 p.m. PDT in Rancho Palos Verdes, California; and the Wells Fargo Healthcare Conference on June 18, 2014 at 9:30 a.m. EDT in Boston, Massachusetts. According to the Company, a live audio webcast along with related presentations will be made available on the HCA Holdings' website under Investor Relations. The full analyst notes on HCA Holdings are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/HCA/report.pdf

--
Thermo Fisher Scientific, Inc. Analyst Notes
On June 5, 2014, Thermo Fisher Scientific, Inc.'s (Thermo Fisher Scientific) stock increased by 1.04%, closing at $119.00. Over the previous six month trading period, Company's stock went up by 18.73%, compared to the Dow Jones Industrial Average which reflected an increase of 5.96%, during the same trading period. The full analyst notes on Thermo Fisher Scientific are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/TMO/report.pdf

--
PTC Therapeutics, Inc. Analyst Notes
On June 5, 2014, PTC Therapeutics, Inc.'s (PTC Therapeutics) stock went up by 9.62%, closing at $24.28. For the past one month trading session, Company stock reflected a significant increase of 30.05%, compared to the Nasdaq Composite which went up by 3.81%, during the same trading session. The full analyst notes on PTC Therapeutics are available to download free of charge at:
http://www.analystsreview.com/Jun-10-2014/PTCT/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED